Journey Medical financials
$6.49+0.93%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17.8M | $16.0M | $16.1M | $17.0M | $15.0M | $13.1M | $12.6M | $14.6M | $14.9M | $13.0M | $15.3M | $34.5M |
| Gross profit | $11.7M | $9.7M | $10.6M | $11.3M | $10.1M | $8.3M | $7.9M | $10.2M | $9.1M | $7.0M | $13.0M | $28.1M |
| Gross margin | 65.6% | 61.0% | 66.1% | 66.2% | 67.1% | 63.5% | 62.9% | 69.4% | 61.4% | 53.9% | 85.3% | 81.4% |
| Operating income | -$215.0K | -$1.5M | -$456.0K | -$2.1M | -$2.9M | -$3.3M | $1.2M | -$2.9M | -$2.9M | -$10.1M | -$2.1M | $17.2M |
| Net income | -$312.0K | -$2.2M | -$1.2M | -$2.3M | -$3.8M | -$4.1M | $1.5M | -$2.4M | -$3.4M | -$10.4M | -$2.1M | $16.8M |
| Net margin | −1.7% | −14.0% | −7.8% | −13.6% | −25.3% | −31.0% | 12.1% | −16.3% | −22.6% | −80.1% | −14.0% | 48.6% |
| Diluted EPS | $-0.01 | $-0.08 | $-0.05 | $-0.09 | $-0.16 | $-0.18 | $0.07 | $-0.12 | $-0.17 | $-0.53 | $-0.13 | $0.80 |
| EBITDA | $754.0K | -$366.0K | $609.0K | -$1.1M | -$1.8M | -$2.3M | $2.2M | -$2.1M | -$2.1M | -$9.3M | -$1.3M | $18.1M |
| Operating cash flow | -$1.7M | $2.9M | -$6.3M | -$2.4M | -$942.0K | -$2.8M | $2.2M | -$1.2M | -$5.2M | -$5.0M | -$16.5M | $18.7M |
| Free cash flow | -$1.7M | $2.9M | -$6.3M | -$2.4M | -$942.0K | -$2.8M | -$12.8M | -$1.2M | -$5.2M | -$5.0M | -$16.5M | $18.7M |
| Diluted shares | 27.5M | 27.3M | 27.1M | 25.0M | 23.3M | 22.6M | 21.4M | 20.5M | 20.0M | 19.8M | 16.1M | 21.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $25.6M | $27.2M | $24.1M | $24.9M | $20.3M | $21.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $25.9M | $25.8M | $25.7M | $25.6M | $25.5M | $25.4M |
| Total assets | $98.4M | $91.5M | $94.6M | $85.2M | $81.2M | $85.0M |
| Total liabilities | $66.2M | $60.7M | $62.7M | $59.3M | $61.9M | $63.4M |
| Shareholders' equity | $32.1M | $30.8M | $31.9M | $25.9M | $19.2M | $21.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology